Table 3 Summary of main secondary variables at week 16 (end of treatment); intention to treat and LOCF analysis.
Variable (range) | Placebo (N= 111) | 25 mg/d Neramexane (N= 106) | 50 mg/d Neramexane (N= 106) | 75 mg/d Neramexane (N= 99) | |
|---|---|---|---|---|---|
THI-12 Emotional-cognitive subscore | (0-14) | -1.7 ± 2.45 | -1.2 ± 2.50 0.145 | -2.0 ± 2.64 0.388 | -1.8 ± 2.59 0.645 |
THI-12 Functional-communicational subscore | (0-10) | -0.7 ± 1.75 | -0.7 ± 1.47 0.859 | -1.2 ± 1.96 0.021* | -1.1 ± 1.77 0.097 |
Tinnitus loudness/severity | (0-10) | -0.7 ± 1.64 | -0.4 ± 1.51 0.279 | -0.9 ± 2.05 0.212 | -0.9 ± 1.56 0.233 |
Tinnitus annoyance | (0-10) | -0.8 ± 2.04 | -0.8 ± 1.95 0.639 | -1.3 ± 2.26 0.043* | -0.8 ± 1.85 0.494 |
Tinnitus impact on life | (0-10) | -1.0 ± 1.98 | -0.6 ± 1.89 0.335 | -1.4 ± 2.61 0.038* | -0.8 ± 2.04 0.924 |
Tinnitus as a problem | (0-10) | -1.1 ± 1.86 | -0.6 ± 1.72 0.058 | -1.3 ± 2.42 0.328 | -0.9 ± 2.05 0.951 |
Hyperacusis as a problem | (0-10) | -0.7 ± 2.51 | -0.5 ± 2.49 0.271 | -0.8 ± 2.72 0.778 | -0.8 ± 1.85 0.666 |
Hearing as a problem | (0-10) | -0.2 ± 1.65 | -0.0 ± 2.01 0.782 | -0.7 ± 1.89 0.088 | -0.1 ± 1.86 0.863 |
CGIC % improvement | 27.9 | 22.6 | 34.0 | 38.4 | |